Navigation Links
Anadys Pharmaceuticals Reports Third Quarter 2007 Financial Results and Operational Highlights
Date:11/1/2007

SAN DIEGO, Nov. 1 /PRNewswire-FirstCall/ -- Anadys Pharmaceuticals, Inc. (Nasdaq: ANDS), a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology, today reported its financial results for the third quarter ended September 30, 2007 and operational highlights.

"The third quarter of 2007 marked an important transition for Anadys," said Steve Worland, Ph.D., President and Chief Executive Officer of Anadys. "We elected to focus investment on our two product candidates we believe most likely to create value, ANA598 for hepatitis C virus infection and ANA773 in oncology. Concurrently, we discontinued development of ANA975 and ANA380 and ceased early discovery efforts."

"We decided to focus on ANA598 and ANA773 based on the demonstrated preclinical properties of these compounds and our anticipation of future clinical benefits," continued Dr. Worland. "We are pleased to announce today that our IND to commence clinical investigation of ANA773 has been accepted by the FDA and we look forward to initiating a trial in cancer patients by the end the year. In parallel, we continue to advance ANA598 through IND enabling studies. We believe that our decision to focus investment on these two product candidates will enable us to achieve meaningful clinical milestones in both programs with our existing cash reserves."

Financial Results

In the third quarter, the Company and its collaborator, Novartis, decided to discontinue the development of ANA975, a Phase 1b compound for the treatment of hepatitis C virus (HCV) infection. Also during the third quarter, Novartis and Anadys concluded that no further activities will be pursued under the c
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... July 30, 2015 , ... GEA's ... designed for continuous operation up to 1500 bar. The sanitary design gauge of ... preventing toxic contamination. , The Pony™ NS2006L homogenizer is an ideal solution for ...
(Date:7/29/2015)... 2015: +14% CER / 20% of sales) led the regional performance in the ... as well as solid contributions from Korea, India and ... Middle East / Africa (Q2 2015: +3% ... Turkey and the United Kingdom . ... U.S. HPV sales, on demand across all customer classes. The top seven emerging ...
(Date:7/29/2015)... , July 29, 2015 ... announced the addition of the "Global Biosimilars ... offering. The Global Biosimilars Market, 2015 ... the rapidly growing biosimilars market. With the blockbuster ... to minimize costs, biosimilars are being viewed as ...
(Date:7/29/2015)... , July 29, 2015  Indivior PLC (LON: ... for naloxone nasal spray was accepted and received Priority ... for the treatment of opioid overdose. This naloxone nasal ... specially formulated for optimal absorption into the nasal mucosa. ... minimal training so individuals may be better equipped to ...
Breaking Biology Technology:GEA Announces the Pony™ NS2006L… a Self-contained, High Pressure Lab Homogenizer for Product Development Ensuring Maximum Efficiency and Safety 2QIAGEN Reports Results for Second Quarter and First Half of 2015 2QIAGEN Reports Results for Second Quarter and First Half of 2015 3QIAGEN Reports Results for Second Quarter and First Half of 2015 4QIAGEN Reports Results for Second Quarter and First Half of 2015 5QIAGEN Reports Results for Second Quarter and First Half of 2015 6QIAGEN Reports Results for Second Quarter and First Half of 2015 7QIAGEN Reports Results for Second Quarter and First Half of 2015 8QIAGEN Reports Results for Second Quarter and First Half of 2015 9QIAGEN Reports Results for Second Quarter and First Half of 2015 10Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5
... The Netherlands, September 26 A consortium of,experts in ... have,joined forces to develop a novel pandemic influenza vaccine ... awarded a grant of,EUR3.5 million from the European Union ... new vaccine. The so-called FluVac project will be,coordinated by ...
... Glycominds Ltd., a biodiagnostics,company specializing in glycan biomarkers ... cancer, announced today that has,entered the Biomolecular Photonic ... the Government of Israel to improve in-vivo imaging ... BMP consortium was,approved for three years and was ...
... NanoBio(R) Corporation, a,biopharmaceutical company developing novel anti-infective topicals ... today announced,the addition of four new scientists to ... Ph.D.; Susan Ciotti, Ph.D.; Robert L. Hagan, Ph.D.,and ... and commercializing,its novel topical anti-infectives and mucosal vaccines. ...
Cached Biology Technology:European Expert Consortium Combines Forces to Develop a Novel Pandemic Influenza Vaccine 2European Expert Consortium Combines Forces to Develop a Novel Pandemic Influenza Vaccine 3Glycominds Joins Biomolecular Photonic (BMP) Consortium to Develop New Molecular Imaging Technique 2NanoBio Expands Drug Development Team for Its Anti-Infective Products 2NanoBio Expands Drug Development Team for Its Anti-Infective Products 3
(Date:7/31/2015)... 31 de julio de 2015 La 10 th ... celebrará por medio de BGI del 22 al 25 de octubre ... Este año, la conferencia celebra su décimo aniversario. ... convertido en una de las reuniones anuales más influyentes del ... las reuniones más dinámicas, entusiastas y mejores a nivel científico. ...
(Date:7/27/2015)... Calif. , July 27, 2015  Synaptics ... of human interface solutions, today announced that Huawei ... touchscreen solution for its stylish smartwatch. Huawei ... its proven reliability, low power and highly responsive ... wet finger. Huawei designers also required a classic ...
(Date:7/21/2015)... 21, 2015  NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market ... that it has filed provisional patent 62/192218 for ... This invention highlights next generation payment ... account, but also the user using unique personal ...
Breaking Biology News(10 mins):La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 2La 10th International Conference on Genomics (ICG-10) se llevará a cabo en octubre 3Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4
... released by the National Institute of Standards and Technology ... vendors to give customers convenient, electronic access to their ... part of the new "Green Button" initiative. Green ... their own energy usage information in an understandable and ...
... a bright 11-year-old who likes to draw detailed maps in his ... physical skills most children take for granted -- running and climbing ... was diagnosed with a form of muscular dystrophy known as Duchenne ... affects about 1 in 3,500 newborns -- mostly boys -- worldwide. ...
... The mystery of how salmon navigate across thousands of ... before journeying upstream to spawn has intrigued biologists for decades, ... the fishes, homing strategy. In the study, scientists examined ... salmon to the Fraser River in British Columbia and ...
Cached Biology News:New guide will allow electric utilities to develop Green Button Web tools 2Experimental gene therapy treatment for Duchenne muscular dystrophy offers hope for youngster 2Experimental gene therapy treatment for Duchenne muscular dystrophy offers hope for youngster 3Experimental gene therapy treatment for Duchenne muscular dystrophy offers hope for youngster 4Salmon may use magnetic field as a navigational aid 2Salmon may use magnetic field as a navigational aid 3
... This is a molecular screening, low ... by molecular sieving. It is recommended for ... in size such as PCR products. Micro ... but is not recommended for blotting techniques. ...
Rabbit polyclonal to Nck alpha ( Abpromise for all tested applications). entrezGeneID: 4690 SwissProtID: P16333...
Sheep polyclonal to Salmonella Thomasville ( Abpromise for all tested applications). Antigen: Native Salmonella thomasville...
Goat polyclonal to HA1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: TLGSCRERQPEFV from the C terminus of human HA1. Entrez GeneID: 23526 Swiss Protein ID: O78181...
Biology Products: